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Abstract
It is well established that the ingestion of the omega-3 (N3) fatty acids docosahexaenoic acid (DHA)
and eicosapentaenoic acid (EPA) positively benefit a variety of health indices. Despite these benefits
the actual intake of fish derived N3 is relatively small in the United States. The primary aim of our
study was to examine a technology capable of delivering omega-3 fatty acids in common foods via
microencapsulation (MicroN3) in young, healthy, active participants who are at low risk for
cardiovascular disease. Accordingly, we randomized 20 participants (25.4 ± 6.2 y; 73.4 ± 5.1 kg) to
receive the double blind delivery of a placebo-matched breakfast meal (~2093 kJ) containing
MicroN3 (450–550 mg EPA/DHA) during a 2-week pilot trial. Overall, we observed no differences
in overall dietary macronutrient intake other than the N3 delivery during our treatment regimen.
Post-test ANOVA analysis showed a significant elevation in mean (SE) plasma DHA (91.18 ± 9.3 vs.
125.58 ± 11.3 umol/L; P < 0.05) and a reduction in triacylglycerols (89.89 ± 12.8 vs. 80.78 ± 10.4
mg/dL; P < 0.05) accompanying the MicroN3 treatment that was significantly different from placebo
(P < 0.05). In post study interviews, participants reported that the ingested food was well-tolerated,
contained no fish taste, odor or gastrointestinal distress accompanying treatment. The use of
MicroN3 foods provides a novel delivery system for the delivery of essential fatty acids. Our study
demonstrates that MicroN3 foods promote the absorption of essential N3, demonstrate
bioactivity within 2 weeks of ingestion and are well tolerated in young, active participants who are
at low risk for cardiovascular disease.
Introduction
Consumption of oily fish or oils rich in the omega-3 fatty
acids (N3) docosahexaenoic acid (DHA) and eicosapen-
taenoic acid (EPA) are well established for their role in
supporting cardiovascular health [1-3]. While the mecha-
nisms surrounding the cardioprotective effects of EPA and
DHA are complex, they can be broadly categorized into
modulations of cardiac function (including antiarrhyth-
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mic effects), hemodynamics (cardiac mechanics), arterial
endothelial function, and the modulation of lipids, in
particular triacylglycerols [2,4].
Despite these benefits the actual intake of fish derived N3
is relatively small in the United States whereby total N3
accounts for 1.6 g/d (0.7% of energy intake). Of this,
about 1.4 g/d is plant derived α-linolenic acid (ALA),
whereas only 0.1 to 0.2 g/d comes from EPA and DHA [2].
Supplementation with N3 capsules is an option; however,
gastrointestinal disturbances and fish odor often contrib-
ute to low compliance. Moreover, little research has been
performed on younger, healthy and active participants at
low risk for cardiovascular disease. It is intuitive, however,
that early prophylaxis via the ingestion of N3 while young
is beneficial for long term health. The aim of our investi-
gation was to perform a pilot trial to test the feasibility of
using foods fortified with microencapsulated fish oil
(MicroN3) to deliver a beneficial daily amount of EPA
and DHA to individuals not regularly consuming fish or
N3 supplement products.
Methods
We obtained written informed consent from 20 partici-
pants (12 men, and 8 women; 20–70 y) in generally good
health, who agreed to maintain their current diet and exer-
cise habits (3–5 days/wk) during the trial. Participants
were excluded if their BMI was <18.5 or >34.9. We also
excluded candidates currently taking an N3 supplement
or eating fish > 1×/wk. Participants were randomized
equally to a treatment or placebo group after completing
all questionnaires inclusive of food frequency measure-
ments. On days 0 and 15 blood was collected for analysis
(see below). On days 1–14, participants reported to our
kitchen to consume a breakfast meal (~2093 kJ). The
treatment breakfast of foods containing MicroN3 (MEG-
3™; Ocean Nutrition, Nova Scotia, Canada) included:
milk, yogurt, and bread products including tortillas and
sliced bread. All of the products we used in our study were
"finished goods" products available in grocery stores in
the United States and Canada. Thus, each product was
made with the MEG-3 ingredient all ready in place. We
did not use the MEG-3 product as a powder that was
mixed into foods. A list of foods currently available can be
found at http://www.meg-3.com. We also incorporated
brown eggs from hens fed flaxseed as hens are able to effi-
ciently convert the ALA derived from flax to DHA [5].
Total EPA/DHA ranged from 450–500 mg/meal. Individ-
uals randomized to the placebo group received macronu-
trient-matched meals. This study protocol was approved
by the Institutional Review Board at The Cooper Institute,
Dallas, TX, USA.
Primary outcomes included plasma concentrations of the
fatty acids EPA and DHA, which are typically associated
with cardiovascular health [2-4]. All plasma fatty acid
analysis was completed in one batch at Metametrix Clini-
cal Laboratory (Norcross, GA, USA) using gas chromatog-
raphy/mass spectrometry [6]. We obtained 12 hour
fasting blood samples from all study participants on days
0 and 15. For plasma samples, we drew one 7 mL EDTA
(lavender) tube, inverted the tube ~10 times and centri-
fuged the sample immediately for 15 minutes. We then
transferred 3 ml of plasma to a transfer tube and kept the
sample frozen until we performed our analysis in batch.
Plasma fatty acids were analyzed in duplicate using gas
chromatography/mass spectrometry (GC/MS). Sample
preparation consists of a methyl esterification reaction
followed by liquid/liquid extraction prior to analysis. To
a 16 × 100 mm glass screw top tube, 2 mL of internal
standard solution was added to 200 μL of plasma. Sam-
ples were vortex mixed followed by a 1.5 mL addition of
reaction solution (1:3 v/v, acetyl chloride:iso-octane).
Sample tubes were capped, vortex mixed, and placed in a
heat block at 100°C for 1 hour. Samples were cooled and
neutralized with 4 mL of potassium carbonate (100 mg/L
in H2O). The samples were vortex mixed and centrifuged
at 3500 RPMs for 10 minutes. The top layer of the bipha-
sic sample solution was extracted into amber auto-sam-
pler vials and loaded on instrument. The samples were
analyzed using an Agilent 6890N GC with autosampler
and an Agilent 5973N mass spectrometer. The analytical
separation was performed on a HP-23 (Cis/Trans FAME
capillary column) 60 m × 0.25 mm × 0.25 mm film thick-
ness. The instrumental and data analysis were performed
using MSD Chem Station.
We also examined plasma lipids and hepatorenal func-
tion, with a particular interest in triacylglycerols as a sur-
rogate clinical feature reflective of the physiologic activity
of N3 supplementation. In order to examine dietary
intake, we used the FIAS system (version 3.9, 2000) devel-
oped at the Human Nutrition Center, University of Texas
Health Science Center School of Public Health. One rea-
son we have selected the FIAS is that it is linked with the
Pyramid Serving Database (PSDB). The USDA food codes
generated after the analysis of the dietary recalls in FIAS
are linked to the PSDB to determine the number of serv-
ings of each major food groups consumed. This database
was developed to analyze the number of servings of each
of the Food Guide Pyramid's major food groups and the
amounts of discretionary fat and sugars consumed [7,8].
As a tertiary area of interest we interviewed participants
after the trial to examine their tolerability of the MicroN3
foods they ingested. As this was a tertiary measure, we did
not use a standardized or validated questionnaire to
examine tolerability parameters.Journal of the International Society of Sports Nutrition 2009, 6:12 http://www.jissn.com/content/6/1/12
Page 3 of 6
(page number not for citation purposes)
Specific questions included:
(1) Were you able to distinguish the foods you ingested by
a fishy odor (Y/N)? If yes, on how many occasions did you
notice this phenomenon?
(2) Did the foods you ingest cause you any gastrointesti-
nal distress such as stomach pain, diarrhea, or belching
(Y/N)? If yes, on how many occasions did you notice this
phenomenon?
(3) Did you notice any fishy aftertaste following the con-
sumption of your breakfast meal (Y/N)? If yes, on how
many occasions did you notice this phenomenon?
(4) Did you notice any fishy odor on your breath or with
belching (Y/N)? If yes, on how many occasions did you
notice this phenomenon?
Statistical Procedures
We compared all baseline characteristics for demograph-
ics and dietary characteristics using a paired t-test. We fur-
ther examined our participant's baseline dietary intake of
N3 fatty acids to the national average of the United States
using a one-sample t-test. This was predicated on reports
detailing the N3 intake within the United States where
total N3 accounts for 1.6 g/d (0.7% of energy intake), 1.4
g/d is plant derived α-linolenic acid (ALA) and 0.1 to 0.2
g/d comes from EPA and DHA [2].
All measures were analyzed for mean within and between
group differences and mean delta scores from baseline
using a 2 × 2 ANCOA for time (pre/post), group (treat-
ment/control) and time-by-treatment interactions. Tukey
post-hoc analyses of statistically significant interactions
were used to determine treatment differences at an alpha
level of P ≤ 0.05. We examined food tolerability indices
using a Chi-Square analysis.
Results
We observed no significant differences for age (25.4 ± 6.6
y), BMI (25.2 ± 1.4 kg/m2), weight (72.9 ± 4.9 kg), or
plasma lipids. We have presented the dietary characteris-
tics of our study cohort in Table 1. Overall, we did not
observe any statistical difference of the dietary macronu-
trient composition between treatment groups at baseline
or following treatment with the exception of the N3 given
to the treated participants. In comparison to reports on
national averages, we observed no significant differences
between our current cohort and previous reports detailing
the N3 intake of those individuals residing the United
States.
As part of their treatment, the MicroN3 treated group
increased their daily intake of EPA/DHA derived N3 by
450–550 mg/d. Following treatment with MicroN3 foods,
our statistical analysis showed a significant elevation in
mean plasma DHA (P < 0.05) and reduction in triacylglyc-
erols within the treatment group (P < 0.05; Table 2).
When expressed as mean delta scores, both the increase in
DHA and decrease in triacylglycerols were significantly
different from placebo (P < 0.05). While plasma EPA
showed a trend to increase in the treatment group, there
was no statistical difference noted between the treatment
and the placebo group (P = 0.08). Lastly, the results of our
tertiary analysis showed no difference between either
treatment group, nor no occurrence of questioned effects
for any of our interview questions. In essence, our inter-
vention showed no occurrences of being able to identify
MicroN3 foods via fish odor from food, gastrointestinal
distress, fishy aftertaste or fish odor on the participant's
breath.
Discussion
The primary findings of our current pilot study show that
MicroN3 fortified foods can increase plasma N3 concen-
trations, while positively modulating triacylglycerols
within 2 weeks in a population who would be considered
to have normal triacylglycerols concentrations. This latter
effect on triacylglycerols is of particular interest as studies
showing a reduction in triacylglycerols typically range
between 2–4 g of N3 ingestion per day [9]. More recent
studies, however, have shown attenuated postprandial tri-
acylglycerols with as little as 1 g/d with chronic adminis-
tration [10]. The results of our study are appealing as the
cohort we examined represents a population similar to
the United States national average and the foods ingested
were well tolerated.
Collectively, higher N3 consumption has the potential to
positively affect many heath issues such as pregnancy,
Table 1: Dietary characteristics of study participants
Placebo (n = 10) MicroN3 (n = 10)
Mean SE Mean SE
Energy (MJ) 6.74 0.7 6.36 0.6
Protein (g) 73.2 4.4 68 4.4
Carbohydrate (g) 198.8 25.4 186.3 25.4
Total Fat (g) 72.1 4.8 65.1 4.8
Sat Fat (g) 19.5 2.0 18.2 2.0
MUFA (g) 22.9 2.3 21.2 2.3
PUFA (g) 14.9 1.7 11.5 1.7
α-Linoleic (g) 13.1 1.5 12.5 1.5
α-Linolenic (g) 1.4 0.2 1.3 0.2
Arachadonic (mg) 10.1 0.3 10.1 0.3
EPA (mg) 10.1 0.3 10.1 0.3
DHA (mg) 10.1 0.2 10.1 0.2
Cholesterol (mg) 215 37.5 202.9 37.5
Fiber (g) 18.7 3.5 16.7 3.5
Alcohol (g) 7.2 1.7 7.6 1.7Journal of the International Society of Sports Nutrition 2009, 6:12 http://www.jissn.com/content/6/1/12
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cognitive development and learning in infants and chil-
dren, visual development, immune and inflammatory
responses, rheumatoid arthritis, ulcerative colitis, Crohn
disease, eczema, asthma, and type 1 diabetes, metabolic
syndrome, type 2 diabetes, obesity, cardiovascular disease
and lipid metabolism, neurologic degeneration and men-
tal health and mood disorders [11,12]. Moreover, the U.S.
Food and Drug Administration has given a qualified
health claim status to EPA and DHA N3 fatty acids, stating
that supportive but not conclusive research shows that
consumption of EPA and DHA may reduce the risk of cor-
onary heart disease [13].
A fundamental difficulty surrounding the recommenda-
tion and ingestion of N3 fatty acids containing high quan-
tities of EPA and DHA is the observation that the highest
concentrations of these fatty acids are found in cold water
fish [14]. Unfortunately, many individuals are resistant to
consuming fish for a variety of reasons including taste,
gastrointestinal distress and fish odor [2]. As an alterna-
tive to fish ingestion or fish oil supplementation, several
studies have examined the effectiveness of ingesting N3
from plant sources, such as flax seed. However, it has been
reported that conversion of ALA to EPA and further to
DHA in humans is limited, but varies with individuals
[15]. For example, it has been reported that women have
higher ALA conversion efficiency than men and that con-
version is greater than expected in non fish-eating vegetar-
ians and non fish-eating meat-eaters than in fish-eaters
[16]. Though the use of N3 fatty acids derived from ALA
should not be dissuaded, the effectiveness of longer chain
are clearly more effective with regard to efficacy. A major
strength of our current pilot study is the suggestion that
the incorporation of N3 into common foods shows prom-
ise given the increase in plasma DHA, modest lowering of
triacylglycerols and lack of side effects reported with
MicroN3 food ingestion.
During the study, we were able to deliver 450–550 mg of
EPA/DHA or half the dosage recommended by the AHA
for patients with documented CHD, and one fourth the
dose recommended for individuals with elevated triacylg-
lycerols in one meal [2]. Perhaps one of the most salient
findings from this study is that MicroN3 food technology
will allow individuals to incorporate N3 more easily into
their regular diet. Thus, it is feasible that N3 rich foods can
be incorporated into a variety of eating patterns that may
be associated with an individual's socioeconomic status,
ethnicity, and corresponding food preferences. Though
we feel that future investigations into the effects of
MicroN3 foods at higher doses, for longer study dura-
tions, and with more robust markers of CHD are of merit,
the true promise of this technology lies in the potential to
deliver long chain N3 fatty acids to individuals not accus-
tomed to nor wanting to ingest fish or fish oil supple-
ments.
Table 2: Lipid and plasma fatty acid characteristics of the study participants
LIPID PROFILE Pre-treatment Post-treatment
Total-C (mmol/L) Control 5.02 ± 0.2 5.06 ± 0.2
Treatment 4.22 ± 2.3 4.21 ± 2.2
LDL-C (mmol/L) Control 3.13 ± 0.2 3.10 ± 0.2
Treatment 2.42 ± 2.2 2.44 ± 2.3
HDL-C (mmol/L) Control 1.39 ± 0.1 1.46 ± 0.1
Treatment 1.34 ± 0.6 1.35 ± 0.7
VLDL-C (mmol/L) Control 0.50 ± 0.0 0.51 ± 0.1
Treatment 0.46 ± 0.7 0.42 ± 0.6
Triacylglycerols (mmol/L)a Control 1.01 ± 0.1 1.10 ± 0.3
Treatment 1.02 ± 0.2 0.91 ± 0.1 b, c
FATTY ACID PROFILE Pre-treatment Post-treatment
ALA (umol/L) Control 22.61 ± 3.4 20.22 ± 2.1
Treatment 23.18 ± 2.3 19.74 ± 1.7
AA (umol/L) Control 670.74 ± 60.1 696.77 ± 87.1
Treatment 599.91 ± 33.9 613.12 ± 27.0
DHA (umol/L)a Control 83.23 ± 10.3 103.23 ± 15.0
Treatment 91.18 ± 9.7 125.58 ± 11.9 b, c
EPA (umol/L) Control 22.49 ± 3.4 20.59 ± 6.8
Treatment 17.93 ± 3.1 20.77 ± 2.9
a Significant overall group × time ANCOVA statistical effect (P < 0.01)
b Represents a significant within group statistical effect (P < 0.05)
c Represents a significant change score different than control (P < 0.05)
Total-C (Total cholesterol), LDL-C (low density cholesterol, HDL-C (high density cholesterol), VLDL (very low density cholesterol)
ALA (alpha-linolenic acid), AA (arachadonic acid), DHA (docosahexaenoic acid), EPA (eicosapentaenoic acid)Journal of the International Society of Sports Nutrition 2009, 6:12 http://www.jissn.com/content/6/1/12
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We realize that certain limitations can be applied to our
current study. First, the sample size was small and that our
intervention was relatively short. These two factors most
certainly influenced a more accurate portrayal of the bio-
distribution of the N3 used in our intervention. This is an
important factor to consider for future trials using
MicroN3 foods as the fraction of N3 (i.e. EPA or DHA) has
specific characteristics for dietary interventions. For exam-
ple, DHA in tissues is particularly abundant in neural and
retinal tissue. Further, dietary DHA results in a dose
dependent, saturable increase in plasma DHA concentra-
tions accompanied by modest increases in EPA concentra-
tions. Likewise, EPA concentrations increase in response
to dietary EPA intake with little increase in DHA concen-
trations. These same observations are also present for tis-
sue concentrations [17,18]. Conversely, a potential
benefit of the MicroN3 technology is that it may allow
specific N3 combinations aimed at health specific needs.
A second limitation to our study is that we did not record
a follow-up food frequency questionnaire. Given that this
was only a 2 week pilot trial we are of the opinion that it
is unlikely that participants changed their diet in such
manner so as alter their overall eating pattern. However,
we cannot discount the possibility. Lastly, we feel that our
study would have benefited from examining the erythro-
cytes for N3 concentration.
The strength of our pilot study is that it confirms our
hypothesis that foods fortified with MicroN3 can serve as
an effective vehicle for the delivery of N3 fatty acids in
young, healthy, active participants. Furthermore, the use
of such a technology should enable both health care prac-
titioners and consumers alike to make N3 ingestion a part
of their normal lifestyle without significantly altering pre-
ferred food choices or incorporating a dietary regimen
requiring the ingestion of supplement capsules. Our study
also demonstrated that a large volume of N3 is easily
administered with the alteration of just one daily meal; in
our case, a breakfast meal. Therefore, it is not unreasona-
ble to postulate that minor alterations in other daily meals
or the augmentation of a capsular supplement routine are
well within the grasp of most individuals.
Conclusion
We conclude that this new food technology shows prom-
ise for the development of functional foods capable of
improving health care outcomes related to N3 ingestion.
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